Advanced search
Publication Cover
OncoTargets and Therapy Volume 10, 2017 - Issue
Submit an article Journal homepage
52
Views
9
CrossRef citations to date
0
Altmetric
Case Report

Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction

Midori Shimada1 Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences;2 Department of Respiratory Medicine, Japanese Red Cross Nagasaki Genbaku Hospital
,
Minoru Fukuda2 Department of Respiratory Medicine, Japanese Red Cross Nagasaki Genbaku Hospital;3 Clinical Oncology Center, Nagasaki University Hospital, Nagasaki, JapanCorrespondence[email protected]
,
Masaaki Fukuda2 Department of Respiratory Medicine, Japanese Red Cross Nagasaki Genbaku Hospital
,
Takeshi Kitazaki2 Department of Respiratory Medicine, Japanese Red Cross Nagasaki Genbaku Hospital
,
Kohji Hashiguchi2 Department of Respiratory Medicine, Japanese Red Cross Nagasaki Genbaku Hospital
,
Takaya Ikeda1 Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences
,
Hiroyuki Yamaguchi1 Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences
,
Katsumi Nakatomi1 Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences
,
Kazuto Ashizawa3 Clinical Oncology Center, Nagasaki University Hospital, Nagasaki, Japan
&
Hiroshi Mukae1 Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences
 show all
Pages 3211-3214 | Published online: 29 Jun 2017

References

  • SodaMChoiYLEnomotoMIdentification of the transforming EML4-ALK fusion gene in non-small-cell lung cancerNature2007448715356156617625570
  • ShawATYeapBYMino-KenudsonMClinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALKJ Clin Oncol200927264247425319667264
  • SasakiTRodigSJChirieacLRJannePAThe biology and treatment of EML4-ALK non-small cell lung cancerEur J Cancer201046101773178020418096
  • SetoTKiuraKNishioMCH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 studyLancet Oncol201314759059823639470
  • ShawATGandhiLGodgeelSAlectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicenter, phase 2 trialLancet Oncol201617223424226708155
  • CamidgeDRBangYJKwakEActivity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase I studyLancet Oncol201213101011101922954507
  • ChristensenJGZouHYArangoMECytoreductive antitumor activity of PF-2341066 a novel inhibitor of anaplastic lymphoma kinase and c-MET, in experimental models of anaplastic large-cell lymphomaMol Cancer Ther2007612 Pt 13314332218089725
  • ZouHYLiQLeeJHAn orally available small-molecule inhibitor of c-MET, PF-2341066, exhibits cyroreductive antitumor efficacy through antiproliferative and antiangiogenic mechanismsCancer Res20076794408441717483355
  • GadgeelSMBeplerGCrizotinib: an anaplastic lymphoma kinase inhibitorFuture Oncol20117894795321823889
  • WangWSongZZhangYResponse to crizotinib in a squamous cell lung carcinoma patient harbouring echinoderm microtubule-associated protein-like 4-anaplastic lymphoma translocation: A case reportThorac Cancer20167335535727148422
  • US Food and Drug AdministrationApproval History XALKORI, NDA no. 202570 Available from: http://labeling.pfizer.com/showlabeling.aspx?id=676Accessed November 15, 2013
  • GastaudLAmbrosettiDOttoJAcute kidney injury following crizotinib administration for non-small-cell lung carcinomaLung Cancer201382236236424001942
  • Martin MartorellPHuerta AlvaroMSolis SalgueroMACrizotinib and renal insufficiency: a case report and review of the literatureLung Cancer201484331031324703892
  • CamidgeDRBrosnanEMDeSilvaCCrizotinib effects on creatinine and non-creatinine-based measures of glomerular filtration rateJ Thorac Oncol20149111634163725436798
  • BrosnanEMWeickhardtAJLuXDrug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small-cell lung cancer treated with the ALK inhibitor crizotinibCancer2014120566467424258622
  • DoebeleRCPillingABAisnerDLMechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancerClin Cancer Res20121851472148222235099
  • ChoiYLSodaMYamashitaYEML4-ALK mutations in lung cancer that confer resistance to ALK inhibitorsN Engl J Med2010363181734173920979473
  • TaniguchiHTakeuchiSFukudaKAmphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitorsCancer Sci20171081536027783866
  • IzzedineHEl-FekihRKPerazellaMAThe renal effects of ALK inhibitorsInvest New Drugs201634564364927468827

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.